Qilu Pharmaceuticals breaks import monopoly in succession

Pharmaceutical Network January 9, 2016 to date, Qilu Pharmaceutical two new drugs - Giffeitini and Lattan, have broken the monopoly of imported drugs on the domestic market, at the same time, its "heavy-duty new drug" by hepatitis B and AIDS two major adaptation certificate approvalIn the view of the Qilu people, the results are a matter of water, at present Qilu Pharmaceuticals has more than 20 antibody drug research and development into the final stage, of which 10 all-innovative drugs, enterprises may usher in a greater harvestlate 2017, Qilu Pharmaceuticals developed the treatment of glaucoma first-line drug Latany, approved by the State Administration of Food andSupervision and Administration of the market, which means that 10 million glaucoma patients have been given a new first-line drug optionend of 2016, Qilu Pharmaceuticals successfully developed and marketed the special drug Giffeitini for non-small cell lung cancer over a period of six years, also breaking the monopoly of foreigngiants on the Chinese market for more than a decadeThe price of the drug is only one-third of the price of the original drug, forcing the price of clinical drugs to drop significantlyalmost in the approval of latta, Qilu Pharmaceuticals in May 2017 for the treatment of AIDS drug tenofort terrier chronic hepatitis B adaptation certificate, also approved by the State General Administration of Food and Drug Administration - tinofuvirestis is also the current domestic chronic hepatitis B clinical treatment of the first-line drugsa year, two first market, three new drugs, four adaptation certificates of clinical first-line drugs, in 2017, Qilu Pharmaceutical's performance brightFor patients, every development of an innovative drug will bring a new choice to the clinic, and every first drug on the market will break the monopoly of imported drugs, so that the price of drugs will be significantly reduced, reducing the burden on patients and the state", as a pharmaceutical, Qilu Pharmaceuticals has always adhered to the idea that the benefit of society, the return of societyThat's what we've been thinking about, and what we've been doingLi Yan, general manager of Qilu Pharmaceuticals, said's impressive achievements in recent years by Qilu Pharmaceuticals seem to be a matter of course for Li YanDrug research and development is not an overnight thing, behind the tireless efforts of researchers for many yearsQilu Pharmaceuticals has a bigger harvest than in 2017: more than 20 antibody drugs are now being developed at different stages of the pipeline, including 10 all-innovative drugs what makes Qilu Pharmaceuticals' success in the ? In the interview reporters found that here, everyone is full of energy Here, young people are growing very fast: "After 90" has also begun to emerge Here, there are high-level "sea return" , but also the local training of "post-80" undergraduate, master's talent to grow into a number of departments of the enterprise ministers Give people full confidence and let them play to their full play The "do something together" atmosphere attracts more people to Qilu Pharmaceuticals and is willing to take root in Qilu Pharmaceuticals at present, Qilu Pharmaceuticals has more than 1,600 research and development team, annual research and development investment accounted for 5% to 8% of sales revenue, no budget cap For 36 years, Qilu Pharmaceuticals has been surviving and developing through continuous scientific and technological innovation, research and development, and the continuous introduction of new products in the early 1980s, Qilu Pharmaceutical son Li Botao put forward the goal of "domestic famous, foreign voice" To this end, Qilu Pharmaceuticals in the standards of the world-class After more than 30 years of development, now Qilu Pharmaceuticals has 8 injection products exported to the United States, and is China's only sterile injection products into the Japanese market pharmaceutical companies, single products have accounted for 95% of the market share of similar products in Japan; Qilu Pharmaceuticals in the core areas of Biomedicine in the United States Seattle, San Francisco, Boston and other places to lay out, build innovative research and development centers, the United States advanced technology and research and development resources, to serve the domestic drug research and development and clinical needs "More than 20 years ago, we 'introduced it', and today, we 'go out' Li Yan said, "Enterprises have a very firm belief in the internationalization strategy of drug research and development, only to achieve the internationalization of research and development, can we achieve a true sense of international development." In the future, there will also be more research and development centers in the forefront of the world's medicine to integrate resources for Chinese enterprises, research and development of more new drugs, good drugs, for the global patient services "